CORRELATION BETWEEN GLUCOCORTICOID RECEPTOR IMMUNOHISTOCHEMICAL EXPRESSION WITH HISTOPATHOLOGICAL SUBTYPE, GRADING, AND MOLECULAR CLASSIFICATION IN INVASIVE BREAST CANCER PATIENTS
HUBUNGAN EKSPRESI IMUNOHISTOKIMIA RESEPTOR GLUKOKORTIKOID DENGAN SUBTIPE HISTOPATOLOGI, GRADING, DAN KLASIFIKASI MOLEKULAR PADA PASIEN KANKER PAYUDARA INVASIF
Abstract
Stress exposure triggers an increase in cortisol which activates physical response to stress signals by binding to glucocorticoid receptor (GR) which then affects tumor immune response and therapy resistance that will worsen the clinical outcomes of breast cancer patients. This study is an observational analytical study of 60 invasive breast cancer samples from Royal Prima Hospital in the period 2023–2025. The histopathological type of invasive breast carcinoma was determined through microscopic examination and classified according to WHO 2019. GR expression was assessed using immunoreactive score (IRS) based on proportion of positive tumor cells and intensity of nuclear staining. Molecular classification was determined based on immunohistochemical examination results of ER, PR, HER2, Ki-67 and then categorized according to American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP). Histopathological grading of invasive breast carcinoma was determined based on Nottingham grading system. Data were analyzed descriptively and analytically using the Kruskal-Wallis test. In this study, there was a significant association between GR expression and histopathological grading (p=0.040). GR expression is associated with poor differentiation and proliferative activity of tumors categorized by histopathological grading.
References
American Cancer Society. Breast Cancer Facts & Figures 2024--2025. Atlanta: American Cancer Society, Inc.; 2024. Available from: https://share.google/5OfAQxygoGrUOJgJZ. Accessed June 7, 2026.
Bray F, Laversanne M, Sung H, et al. Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2024;74(3):229-263. doi:10.3322/caac.21834
Kementerian Kesehatan Republik Indonesia. Strategi Indonesia dalam Upaya Melawan Kanker. 2024. Available from:https://repository.kemkes.go.id/book/1379. Accessed June 7, 2026.
Vignjević Petrinović S, Milošević MS, Marković D, Momčilović S. Interplay between stress and cancer—A focus on inflammation. Front Physiol. 2023;14. doi:10.3389/fphys.2023.1119095
Moore JX, Andrzejak SE, Bevel MS, Jones SR, Tingen MS. Exploring racial disparities on the association between allostatic load and cancer mortality: A retrospective cohort analysis of NHANES, 1988 through 2019. SSM - Popul Heal. 2022;19. doi:10.1016/j.ssmph.2022.101185
Vignjević Petrinović S, Milošević MS, Marković D, Momčilović S. Interplay between stress and cancer—A focus on inflammations. Front Physiol. 2023;14. doi:10.3389/fphys.2023.1119095
Butz H, Patócs A. Mechanisms behind context-dependent role of glucocorticoids in breast cancer progression. Cancer Metastasis Rev. 2022;41(4):803-832. doi:10.1007/s10555-022-10047-1
Tsourlakis MC, Kind S, Dwertmann Rico S, et al. Glucocorticoid Receptor (GR) Expression in Human Tumors: A Tissue Microarray Study on More than 14,000 Tumors. Biomedicines. 2025;13(7). doi:10.3390/biomedicines13071683
Mitre-Aguilar IB, Moreno-Mitre D, Melendez-Zajgla J, et al. The Role of Glucocorticoids in Breast Cancer Therapy. Curr Oncol. 2023;30(1):298-314. doi:10.3390/curroncol30010024
Al-Alem U, Mahmoud AM, Batai K, et al. Genetic Variation and Immunohistochemical Localization of the Glucocorticoid Receptor in Breast Cancer Cases from the Breast Cancer Care in Chicago Cohort. Cancers (Basel). 2021;13(10):2261. doi:10.3390/cancers13102261
Mitre-Aguilar IB, Moreno-Mitre D, Melendez-Zajgla J, et al. The Role of Glucocorticoids in Breast Cancer Therapys. Curr Oncol. 2023;30(1):298-314. doi:10.3390/curroncol30010024
Ross DS, Pareja F. Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations. Pathology. 2022;14(3):455-457. doi:10.1016/j.path.2021.05.009
Butz H, Vereczki V, Budai B, et al. Glucocorticoid Receptor Isoforms in Breast Cancer Raise Implications for Personalised Supportive Therapies. Int J Mol Sci. 2024;25(21):11813. doi:10.3390/ijms252111813
Clark AB, Conzen SD. Glucocorticoid receptor-mediated oncogenic activity is dependent on breast cancer subtype. J Steroid Biochem Mol Biol. 2024;243. doi:10.1016/j.jsbmb.2024.106518
Matossian MD, Shiang C, Dolcen DN, et al. High Tumor Glucocorticoid Receptor Expression in Early-Stage, Triple-Negative Breast Cancer Is Associated with Increased T-Regulatory Cell Infiltration. Breast Cancer Res Treat. 2025;209(3):563-572. doi:10.1007/s10549-024-07515-3
Prekovic S, Chalkiadakis T, Roest M, et al. Luminal Breast Cancer Identity Is Determined by Loss of Glucocorticoid Receptor Activity. EMBO Mol Med. 2023;15(12):e17737. doi:10.15252/emmm.202317737
Kumar R. Role of Glucocorticoid Receptor in Triple-Negative Breast Cancer. Receptors. 2025;4(2):8. doi:10.3390/receptors4020008
Bakour N, Moriarty F, Moore G, Robson T, Annett SL. Prognostic Significance of Glucocorticoid Receptor Expression in Cancer. Cancers (Basel). 2021;13(7):1649. doi:10.3390/cancers13071649
Effah W, Ponnusamy S, Asemota S, Khosrosereski Y, Narayanan R. Context Dependent Role of Glucocorticoids in Breast Cancer. Cancer Res. 2024;84(6). doi:10.1158/1538-7445.AM2024-6281
Gandhi S, Elkhanany A, Oshi M, et al. Contribution of immune cells to glucocorticoid receptor expression in breast cancer. Int J Mol Sci. 2020;21(13):1-17. doi:10.3390/ijms21134635
Baker GM, Murphy T, Block T, Nguyen D, Lynch FJ. Development and validation of an immunohistochemistry assay to assess glucocorticoid receptor expression for clinical trials of mifepristone in breast cancer. Cancer Manag Res 2015;7:361–368
Copyright (c) 2027 Dwi Zahra Putri Joneva, Jessy Chrestella, Betty, Causa Trisna Mariedina, Devi Nafilah Yuzar
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
